Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL DIALYSIS CONCENTRATES MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL DIALYSIS CONCENTRATES SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL DIALYSIS CONCENTRATES MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S FIVE FORCES MODEL
6 INDUSTRY INSIGHTS
6.1 MICRO AND MACRO ECONOMIC FACTORS
6.2 PENETRATION AND GROWTH PROSPECT MAPPING
6.3 KEY PRICING STRATEGIES
6.4 INTERVIEWS WITH SPECIALIST
6.5 ANALYIS AND RECOMMENDATION
7 INTELLECTUAL PROPERTY (IP) PORTFOLIO
7.1 PATENT QUALITY AND STRENGTH
7.2 PATENT FAMILIES
7.3 LICENSING AND COLLABORATIONS
7.4 COMPETITIVE LANDSCAPE
7.5 IP STRATEGY AND MANAGEMENT
7.6 OTHER
8 COST ANALYSIS BREAKDOWN
9 TECHNONLOGY ROADMAP
10 PROCEDURE TREND
11 INNOVATION TRACKER AND STRATEGIC ANALYSIS
11.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
11.1.1 JOINT VENTURES
11.1.2 MERGERS AND ACQUISITIONS
11.1.3 LICENSING AND PARTNERSHIP
11.1.4 TECHNOLOGY COLLABORATIONS
11.1.5 STRATEGIC DIVESTMENTS
11.2 NUMBER OF PRODUCTS IN DEVELOPMENT
11.3 STAGE OF DEVELOPMENT
11.4 TIMELINES AND MILESTONES
11.5 INNOVATION STRATEGIES AND METHODOLOGIES
11.6 RISK ASSESSMENT AND MITIGATION
11.7 FUTURE OUTLOOK
12 REGULATORY COMPLIANCE
12.1 REGULATORY AUTHORITIES
12.2 REGULATORY CLASSIFICATIONS
12.3 REGULATORY SUBMISSIONS
12.4 INTERNATIONAL HARMONIZATION
12.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS
12.6 REGULATORY CHALLENGES AND STRATEGIES
13 REIMBURSEMENT FRAMEWORK
14 OPPUTUNITY MAP ANALYSIS
15 VALUE CHAIN ANALYSIS
16 HEALTHCARE ECONOMY
16.1 HEALTHCARE EXPENDITURE
16.2 CAPITAL EXPENDITURE
16.3 CAPEX TRENDS
16.4 CAPEX ALLOCATION
16.5 FUNDING SOURCES
16.6 INDUSTRY BENCHMARKS
16.7 GDP RATION IN OVERALL GDP
16.8 HEALTHCARE SYSTEM STRUCTURE
16.9 GOVERNMENT POLICIES
16.1 ECONOMIC DEVELOPMENT
17 GLOBAL DIALYSIS CONCENTRATES MARKET, BY TYPE
17.1 BICARBONATE CONCENTRATES
17.1.1 BY TYPE
17.1.1.1. POWDER FORM
17.1.1.1.1. MARKET VALUE (USD)
17.1.1.1.2. MARKET VOLUME (UNITS)
17.1.1.1.3. AVERAGE SELLING PRICE (USD)
17.1.1.2. LIQUID FORM
17.1.1.2.1. MARKET VALUE (USD)
17.1.1.2.2. MARKET VOLUME (UNITS)
17.1.1.2.3. AVERAGE SELLING PRICE (USD)
17.1.2 BY VOLUME
17.1.2.1. BELOW 5 L
17.1.2.2. 5 -8 L
17.1.2.3. 10 L
17.1.2.4. 100L
17.1.2.5. 200L
17.1.2.6. 500L
17.1.2.7. 1200L
17.1.2.8. 1500L
17.1.2.9. OTHERS
17.1.3 BY PACKAGING
17.1.3.1. DRUMS/CANSISTER
17.1.3.2. BAGS/CASE
17.1.3.3. OTHERS
17.1.4 BY APPLICATION
17.1.4.1. HEMODIALYSIS
17.1.4.2. PERITONEAL DIALYSIS
17.2 ACIDIC CONCENTRATES
17.2.1 BY TYPE
17.2.1.1. POWDER FORM
17.2.1.1.1. MARKET VALUE (USD)
17.2.1.1.2. MARKET VOLUME (UNITS)
17.2.1.1.3. AVERAGE SELLING PRICE (USD)
17.2.1.2. LIQUID FORM
17.2.1.2.1. MARKET VALUE (USD)
17.2.1.2.2. MARKET VOLUME (UNITS)
17.2.1.2.3. AVERAGE SELLING PRICE (USD)
17.2.2 BY VOLUME
17.2.2.1. BELOW 5 L
17.2.2.2. 5 -8 L
17.2.2.3. 10 L
17.2.2.4. 100L
17.2.2.5. 200L
17.2.2.6. 500L
17.2.2.7. 1200L
17.2.2.8. 1500L
17.2.2.9. OTHERS
17.2.3 BY PACKAGING
17.2.3.1. DRUMS/CANSISTER
17.2.3.2. BAGS/CASE
17.2.3.3. OTHERS
17.2.4 BY APPLICATION
17.2.4.1. HEMODIALYSIS
17.2.4.2. PERITONEAL DIALYSIS
17.3 OTHERS
18 GLOBAL DIALYSIS CONCENTRATES MARKET, BY APPLICATION
18.1 OVERVIEW
18.2 HEMODIALYSIS
18.2.1 BY FREQUENCY
18.2.1.1. NOCTURNAL DIALYSIS
18.2.1.2. INTERMITTENT DIALYSIS
18.2.1.3. DAILY DIALYSIS
18.3 PERITONEAL DIALYSIS
18.3.1 CONTINUOUS AMBULATORY PERITONEAL DIALYSIS (CAPD)
18.3.2 CONTINUOUS CYCLING PERITONEAL DIALYSIS (CCPD)
19 GLOBAL DIALYSIS CONCENTRATES MARKET, BY INDICATIION
19.1 ACUTE KIDNEY INFECTIONS
19.2 END-STAGE RENAL DISEASE (ESRD)
19.3 PERICARDITITS
19.4 LIFE-THREATENING HYPERKALEMIA
19.5 REFRACTORY ACIDOSIS
19.6 SEPTIC SHOCK
19.7 MULTI-ORGAN FAILURE
19.8 OTHERS
20 GLOBAL DIALYSIS CONCENTRATES MARKET, BY LOCATION
20.1 OVERVIEW
20.2 FACILITY BASED
20.2.1 IN-CENTER DIALYSIS
20.2.2 INDEPENDENT DIALYSIS
20.2.3 OTHERS
20.3 HOME-BASED
21 GLOBAL DIALYSIS CONCENTRATES MARKET, BY END USER
21.1 OVERVIEW
21.2 HOSPITALS
21.2.1 PRIVATE
21.2.1.1. TIER 1
21.2.1.2. TIER 2
21.2.1.3. TIER 3
21.2.2 PUBLIC
21.2.2.1. TIER 1
21.2.2.2. TIER 2
21.2.2.3. TIER 3
21.3 CLINICS AND DIALYSIS CENTERS
21.4 HOME CARE SETTING
21.5 OTHERS
22 GLOBAL DIALYSIS CONCENTRATES MARKET, BY DISTRIBUTION CHANNEL
22.1 OVERVIEW
22.2 DIRECT TENDER
22.3 RETAIL SALES
22.3.1 ONLINE
22.3.2 OFFLINE
22.4 OTHERS
23 GLOBAL DIALYSIS CONCENTRATES MARKET, SWOT AND DBMR ANALYSIS
24 GLOBAL DIALYSIS CONCENTRATES MARKET, COMPANY LANDSCAPE
24.1 COMPANY SHARE ANALYSIS: GLOBAL
24.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
24.3 COMPANY SHARE ANALYSIS: EUROPE
24.4 COMPANY SHARE ANALYSIS: ASIA PACIFIC
24.5 MERGERS & ACQUISITIONS
24.6 NEW PRODUCT DEVELOPMENT & APPROVALS
24.7 EXPANSIONS
24.8 REGULATORY CHANGES
24.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
25 GLOBAL DIALYSIS CONCENTRATES MARKET, BY GEOGRAPHY
GLOBAL DIALYSIS CONCENTRATES MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
25.1 NORTH AMERICA
25.1.1 U.S.
25.1.2 CANADA
25.1.3 MEXICO
25.2 EUROPE
25.2.1 GERMANY
25.2.2 FRANCE
25.2.3 U.K.
25.2.4 HUNGARY
25.2.5 LITHUANIA
25.2.6 AUSTRIA
25.2.7 IRELAND
25.2.8 NORWAY
25.2.9 POLAND
25.2.10 ITALY
25.2.11 SPAIN
25.2.12 RUSSIA
25.2.13 TURKEY
25.2.14 NETHERLANDS
25.2.15 SWITZERLAND
25.2.16 REST OF EUROPE
25.3 ASIA-PACIFIC
25.3.1 JAPAN
25.3.2 CHINA
25.3.3 SOUTH KOREA
25.3.4 INDIA
25.3.5 AUSTRALIA
25.3.6 SINGAPORE
25.3.7 THAILAND
25.3.8 MALAYSIA
25.3.9 INDONESIA
25.3.10 PHILIPPINES
25.3.11 VIETNAM
25.3.12 REST OF ASIA-PACIFIC
25.4 SOUTH AMERICA
25.4.1 BRAZIL
25.4.2 ARGENTINA
25.4.3 PERU
25.4.4 COLOMBIA
25.4.5 VENEZUELA
25.4.6 REST OF SOUTH AMERICA
25.5 MIDDLE EAST AND AFRICA
25.5.1 SOUTH AFRICA
25.5.2 SAUDI ARABIA
25.5.3 UAE
25.5.4 EGYPT
25.5.5 KUWAIT
25.5.6 ISRAEL
25.5.7 REST OF MIDDLE EAST AND AFRICA
25.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
26 GLOBAL DIALYSIS CONCENTRATES MARKET, SWOT AND DBMR ANALYSIS
27 GLOBAL DIALYSIS CONCENTRATES MARKET, COMPANY PROFILE
27.1 HUONS MEDITECH
27.1.1 COMPANY OVERVIEW
27.1.2 REVENUE ANALYSIS
27.1.3 GEOGRAPHIC PRESENCE
27.1.4 PRODUCT PORTFOLIO
27.1.5 RECENT DEVELOPMENTS
27.2 NIPRO MEDICAL CORPORATION
27.2.1 COMPANY OVERVIEW
27.2.2 REVENUE ANALYSIS
27.2.3 GEOGRAPHIC PRESENCE
27.2.4 PRODUCT PORTFOLIO
27.2.5 RECENT DEVELOPMENTS
27.3 FRESENIUS
27.3.1 COMPANY OVERVIEW
27.3.2 REVENUE ANALYSIS
27.3.3 GEOGRAPHIC PRESENCE
27.3.4 PRODUCT PORTFOLIO
27.3.5 RECENT DEVELOPMENTS
27.4 ROCKWELL MEDICAL, INC.
27.4.1 COMPANY OVERVIEW
27.4.2 REVENUE ANALYSIS
27.4.3 GEOGRAPHIC PRESENCE
27.4.4 PRODUCT PORTFOLIO
27.4.5 RECENT DEVELOPMENTS
27.5 STERIS CORP
27.5.1 COMPANY OVERVIEW
27.5.2 REVENUE ANALYSIS
27.5.3 GEOGRAPHIC PRESENCE
27.5.4 PRODUCT PORTFOLIO
27.5.5 RECENT DEVELOPMENTS
27.6 DIALIFE SA
27.6.1 COMPANY OVERVIEW
27.6.2 REVENUE ANALYSIS
27.6.3 GEOGRAPHIC PRESENCE
27.6.4 PRODUCT PORTFOLIO
27.6.5 RECENT DEVELOPMENTS
27.7 GUANGDONG BIOLIGHT MEDITECH CO., LTD
27.7.1 COMPANY OVERVIEW
27.7.2 REVENUE ANALYSIS
27.7.3 GEOGRAPHIC PRESENCE
27.7.4 PRODUCT PORTFOLIO
27.7.5 RECENT DEVELOPMENTS
27.8 SWS HEMODIALYSIS CARE CO., LTD
27.8.1 COMPANY OVERVIEW
27.8.2 REVENUE ANALYSIS
27.8.3 GEOGRAPHIC PRESENCE
27.8.4 PRODUCT PORTFOLIO
27.8.5 RECENT DEVELOPMENTS
27.9 ALLMED MEDICAL
27.9.1 COMPANY OVERVIEW
27.9.2 REVENUE ANALYSIS
27.9.3 GEOGRAPHIC PRESENCE
27.9.4 PRODUCT PORTFOLIO
27.9.5 RECENT DEVELOPMENTS
27.1 FARMASOL
27.10.1 COMPANY OVERVIEW
27.10.2 REVENUE ANALYSIS
27.10.3 GEOGRAPHIC PRESENCE
27.10.4 PRODUCT PORTFOLIO
27.10.5 RECENT DEVELOPMENTS
27.11 B. BRAUN SE
27.11.1 COMPANY OVERVIEW
27.11.2 REVENUE ANALYSIS
27.11.3 GEOGRAPHIC PRESENCE
27.11.4 PRODUCT PORTFOLIO
27.11.5 RECENT DEVELOPMENTS
27.12 INSPRAMED
27.12.1 COMPANY OVERVIEW
27.12.2 REVENUE ANALYSIS
27.12.3 GEOGRAPHIC PRESENCE
27.12.4 PRODUCT PORTFOLIO
27.12.5 RECENT DEVELOPMENTS
27.13 PT. HICLEARANCE MEDICAL GLOBAL.
27.13.1 COMPANY OVERVIEW
27.13.2 REVENUE ANALYSIS
27.13.3 GEOGRAPHIC PRESENCE
27.13.4 PRODUCT PORTFOLIO
27.13.5 RECENT DEVELOPMENTS
27.14 BAXTER.
27.14.1 COMPANY OVERVIEW
27.14.2 REVENUE ANALYSIS
27.14.3 GEOGRAPHIC PRESENCE
27.14.4 PRODUCT PORTFOLIO
27.14.5 RECENT DEVELOPMENTS
27.15 ADVIN DIALYSIS
27.15.1 COMPANY OVERVIEW
27.15.2 REVENUE ANALYSIS
27.15.3 GEOGRAPHIC PRESENCE
27.15.4 PRODUCT PORTFOLIO
27.15.5 RECENT DEVELOPMENTS
27.16 WEGO TERUMO (WEIHAI) MEDICAL PRODUCTS CO., LTD
27.16.1 COMPANY OVERVIEW
27.16.2 REVENUE ANALYSIS
27.16.3 GEOGRAPHIC PRESENCE
27.16.4 PRODUCT PORTFOLIO
27.16.5 RECENT DEVELOPMENTS
27.17 XYLEM.
27.17.1 COMPANY OVERVIEW
27.17.2 REVENUE ANALYSIS
27.17.3 GEOGRAPHIC PRESENCE
27.17.4 PRODUCT PORTFOLIO
27.17.5 RECENT DEVELOPMENTS
27.18 SURNI PHARMACEUTICALS
27.18.1 COMPANY OVERVIEW
27.18.2 REVENUE ANALYSIS
27.18.3 GEOGRAPHIC PRESENCE
27.18.4 PRODUCT PORTFOLIO
27.18.5 RECENT DEVELOPMENTS
27.19 TREET GROUP OF COMPANIES(RENACON PHARMA LTD.)
27.19.1 COMPANY OVERVIEW
27.19.2 REVENUE ANALYSIS
27.19.3 GEOGRAPHIC PRESENCE
27.19.4 PRODUCT PORTFOLIO
27.19.5 RECENT DEVELOPMENTS
27.2 IMAEC
27.20.1 COMPANY OVERVIEW
27.20.2 REVENUE ANALYSIS
27.20.3 GEOGRAPHIC PRESENCE
27.20.4 PRODUCT PORTFOLIO
27.20.5 RECENT DEVELOPMENTS
27.21 BROWNDOVE HEALTHCARE (P) LTD
27.21.1 COMPANY OVERVIEW
27.21.2 REVENUE ANALYSIS
27.21.3 GEOGRAPHIC PRESENCE
27.21.4 PRODUCT PORTFOLIO
27.21.5 RECENT DEVELOPMENTS
27.22 MEDICAL SOLUTIONS INTERNATIONAL
27.22.1 COMPANY OVERVIEW
27.22.2 REVENUE ANALYSIS
27.22.3 GEOGRAPHIC PRESENCE
27.22.4 PRODUCT PORTFOLIO
27.22.5 RECENT DEVELOPMENTS
27.23 MEDIVATOR INC (A CANTEL COMPANY) (STERIS )
27.23.1 COMPANY OVERVIEW
27.23.2 REVENUE ANALYSIS
27.23.3 GEOGRAPHIC PRESENCE
27.23.4 PRODUCT PORTFOLIO
27.23.5 RECENT DEVELOPMENTS
27.24 CMS
27.24.1 COMPANY OVERVIEW
27.24.2 REVENUE ANALYSIS
27.24.3 GEOGRAPHIC PRESENCE
27.24.4 PRODUCT PORTFOLIO
27.24.5 RECENT DEVELOPMENTS
28 RELATED REPORTS
29 CONCLUSION
30 QUESTIONNAIRE
31 ABOUT DATA BRIDGE MARKET RESEARCH
